PSE bill moves in legislative queue
This article was originally published in The Tan Sheet
Sen. Dianne Feinstein's, D-Calif., Combat Methamphetamine Enhancement Act, S. 256, moves to the Senate floor for debate. The legislation would require retailers selling cold products with methamphetamine precursors - pseudoephedrine and ephedrine - to train employees on compliance with sales restrictions required by a 2006 law. The Judiciary Committee on March 5 approved the bill, which will be considered by the full Senate on a date to be determined, staff said March 23 (1"The Tan Sheet" March 9, 2009, p. 8)
You may also be interested in...
Omnibus stalls: Congress March 6 extends a continuing resolution to fund most federal agencies through March 11 at fiscal 2008 levels while the House and Senate continue deliberating an omnibus package covering the rest of fiscal 2009. The previous continuing resolution expired March 6 (1"The Tan Sheet" Oct. 6, 2008, p. 9). The House Feb. 25 passed a $410 billion dollar omnibus package, H.R. 1105, including $2.6 billion for FDA, but the bill has stalled in the Senate (2"The Tan Sheet" March 2, 2009, p. 9). Votes are expected March 9 on Republican amendments and March 10 on the Senate's version of the omnibus covering federal agencies other than the departments of Defense and Homeland Security, which were funded in separate legislation Congress enacted in 2008
Biocon has reported FDA clearance for its Malaysian insulin facility, while Lupin and Xellia have also received plant approvals. Meanwhile, Alembic has seen mixed fortunes, receiving both Form 483 observations and an EIR.
Lannett has begun marketing a US rival to Adderall XR through a partnership with Elite and SunGen. But the product will face competition from a range of other generics.